"Ozempic breath" is boosting Hershey's sales of mints and gum
Hershey is experiencing increased sales of its mint and gum products, such as Ice Breakers, due to rising demand from users of GLP-1 weight-loss drugs like Ozempic and Wegovy. While these drugs suppress appetite and may reduce snack consumption, they are associated with a side effect known as 'Ozempic breath,' which has led consumers to use more breath fresheners. Hershey's CEO Kirk Tanner attributed the 8% quarterly sales increase in mints and gum to this trend, though medical professionals note that bad breath is not an officially listed side effect and is still under study.
Opening excerpt (first ~120 words) tap to expand
MoneyWatch "Ozempic breath" is boosting Hershey's sales of mints and gum .chip { background-image: url('/fly/bundles/cbsnewscore/images/chip-bgd/chip-bgd-moneywatch.jpg'); } By Megan Cerullo Megan Cerullo Reporter, MoneyWatch Megan Cerullo is a New York-based reporter for CBS MoneyWatch covering small business, workplace, health care, consumer spending and personal finance topics. She regularly appears on CBS News 24/7 to discuss her reporting. Read Full Bio Megan Cerullo April 30, 2026 / 5:59 PM EDT / CBS News Add CBS News on Google Candy giant Hershey is getting a sales boost from an unexpected consumer segment: users of GLP-1 weight-loss drugs.Hershey CEO Kirk Tanner said in the company's first-quarter earnings call on Thursday that while appetite suppressants are leading customers to…
Excerpt limited to ~120 words for fair-use compliance. The full article is at CBS News — Top.
Discussion
0 commentsMore from CBS News — Top
